Literature DB >> 26297204

Lung cancer: Biology and treatment options.

Hassan Lemjabbar-Alaoui1, Omer Ui Hassan1, Yi-Wei Yang1, Petra Buchanan1.   

Abstract

Lung cancer remains the leading cause of cancer mortality in men and women in the U.S. and worldwide. About 90% of lung cancer cases are caused by smoking and the use of tobacco products. However, other factors such as radon gas, asbestos, air pollution exposures, and chronic infections can contribute to lung carcinogenesis. In addition, multiple inherited and acquired mechanisms of susceptibility to lung cancer have been proposed. Lung cancer is divided into two broad histologic classes, which grow and spread differently: small-cell lung carcinomas (SCLCs) and non-small cell lung carcinomas (NSCLCs). Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, and targeted therapy. Therapeutic-modalities recommendations depend on several factors, including the type and stage of cancer. Despite the improvements in diagnosis and therapy made during the past 25 years, the prognosis for patients with lung cancer is still unsatisfactory. The responses to current standard therapies are poor except for the most localized cancers. However, a better understanding of the biology pertinent to these challenging malignancies, might lead to the development of more efficacious and perhaps more specific drugs. The purpose of this review is to summarize the recent developments in lung cancer biology and its therapeutic strategies, and discuss the latest treatment advances including therapies currently under clinical investigation.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immunotherapies; Lung cancer; Mesothelioma; Non-Small Cell Lung; Small-cell lung carcinomas; Surgery; Targeted therapies; Therapies; Treatments

Mesh:

Substances:

Year:  2015        PMID: 26297204      PMCID: PMC4663145          DOI: 10.1016/j.bbcan.2015.08.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  293 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

2.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung.

Authors:  M C Perry; W L Eaton; K J Propert; J H Ware; B Zimmer; A P Chahinian; A Skarin; R W Carey; H Kreisman; C Faulkner
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

Review 5.  Postoperative radiotherapy for non-small cell lung cancer.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

6.  Surgical treatment for brain metastases: prognostic factors and survival in 177 patients.

Authors:  Andreas M Stark; Hauke Tscheslog; Ralf Buhl; Janka Held-Feindt; H Maximilian Mehdorn
Journal:  Neurosurg Rev       Date:  2004-12-18       Impact factor: 3.042

7.  In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.

Authors:  Andries M Bergman; Paul P Eijk; Veronique W T Ruiz van Haperen; Kees Smid; Gijsbert Veerman; Isabelle Hubeek; Paul van den Ijssel; Bauke Ylstra; Godefridus J Peters
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

8.  Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

Authors:  Daniel D Karp; Luis G Paz-Ares; Silvia Novello; Paul Haluska; Linda Garland; Felipe Cardenal; L Johnetta Blakely; Peter D Eisenberg; Corey J Langer; George Blumenschein; Faye M Johnson; Stephanie Green; Antonio Gualberto
Journal:  J Clin Oncol       Date:  2009-04-20       Impact factor: 44.544

9.  Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.

Authors:  Rakesh Kumar; Victoria B Knick; Sharon K Rudolph; Jennifer H Johnson; Renae M Crosby; Ming-Chih Crouthamel; Teresa M Hopper; Charles G Miller; Laura E Harrington; James A Onori; Robert J Mullin; Tona M Gilmer; Anne T Truesdale; Andrea H Epperly; Amogh Boloor; Jeffrey A Stafford; Deirdre K Luttrell; Mui Cheung
Journal:  Mol Cancer Ther       Date:  2007-07       Impact factor: 6.261

Review 10.  Targeted therapies for non-small cell lung cancer.

Authors:  Wolfram C M Dempke; Tamas Suto; Martin Reck
Journal:  Lung Cancer       Date:  2009-11-14       Impact factor: 5.705

View more
  251 in total

1.  Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios.

Authors:  Rozina Aktar; Antje Dietrich; Falk Tillner; Shady Kotb; Steffen Löck; Henning Willers; Michael Baumann; Mechthild Krause; Rebecca Bütof
Journal:  Br J Radiol       Date:  2018-10-11       Impact factor: 3.039

2.  Small molecular peptide-ScFv αvβ3 conjugates specifically inhibit lung cancer cell growth in vitro and in vivo.

Authors:  Qianqian Qiu; Qiongyao Wang; Changxu Deng; Yanqin Sun; Taoliang Chen; Linlang Guo; Fan Zhang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

3.  Genomic variations in the counterpart normal controls of lung squamous cell carcinomas.

Authors:  Dalin Zhang; Liwei Qu; Bo Zhou; Guizhen Wang; Guangbiao Zhou
Journal:  Front Med       Date:  2017-11-28       Impact factor: 4.592

Review 4.  DNA repair pathways and their roles in drug resistance for lung adenocarcinoma.

Authors:  Altan Kara; Aykut Özgür; Sinem Nalbantoğlu; Abdullah Karadağ
Journal:  Mol Biol Rep       Date:  2021-04-15       Impact factor: 2.316

5.  Cytotoxic action of methylquercetins in human lung adenocarcinoma cells.

Authors:  Katrin Sak; Helen Lust; Marju Kase; Jana Jaal
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

6.  Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.

Authors:  Claudia Stumpf; Daniel Kaemmerer; Elisa Neubauer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

7.  Prognostic significance of histologic subtype in pStage I lung adenocarcinoma.

Authors:  Nozomu Motono; Takuma Matsui; Yuichiro Machida; Katsuo Usuda; Hidetaka Uramoto
Journal:  Med Oncol       Date:  2017-04-21       Impact factor: 3.064

8.  Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.

Authors:  Yanchun Ma; Kun Chen; Zhenhua Yang; Ming Guan
Journal:  Oncol Lett       Date:  2018-01-25       Impact factor: 2.967

Review 9.  Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.

Authors:  Lisa Brusselmans; Lieselot Arnouts; Charissa Millevert; Joyce Vandersnickt; Jan P van Meerbeeck; Kevin Lamote
Journal:  Transl Lung Cancer Res       Date:  2018-10

10.  Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.

Authors:  Mauricio S Caetano; Ahmed I Younes; Hampartsoum B Barsoumian; Michael Quigley; Hari Menon; Chan Gao; Thomas Spires; Timothy P Reilly; Alexandra P Cadena; Taylor R Cushman; Jonathan E Schoenhals; Ailin Li; Quynh-Nhu Nguyen; Maria Angelica Cortez; James W Welsh
Journal:  Clin Cancer Res       Date:  2019-09-20       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.